ATE459647T1 - Humane il-18 substitutionsmutanten und deren konjugate - Google Patents

Humane il-18 substitutionsmutanten und deren konjugate

Info

Publication number
ATE459647T1
ATE459647T1 AT04759472T AT04759472T ATE459647T1 AT E459647 T1 ATE459647 T1 AT E459647T1 AT 04759472 T AT04759472 T AT 04759472T AT 04759472 T AT04759472 T AT 04759472T AT E459647 T1 ATE459647 T1 AT E459647T1
Authority
AT
Austria
Prior art keywords
conjugates
human
substitution mutants
mutants
substitution
Prior art date
Application number
AT04759472T
Other languages
English (en)
Inventor
Narendra Bam
Jacab Bongers
Robert Kirkpatrick
Cheryl JANSON
Kyung Johanson
Zdenka Jonak
Xiayang Qiu
Ping-Yang Yeh
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE459647T1 publication Critical patent/ATE459647T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04759472T 2003-04-15 2004-04-13 Humane il-18 substitutionsmutanten und deren konjugate ATE459647T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46294703P 2003-04-15 2003-04-15
PCT/US2004/011309 WO2004091517A2 (en) 2003-04-15 2004-04-13 Conjugates comprising human il-18 and substitution mutants thereof

Publications (1)

Publication Number Publication Date
ATE459647T1 true ATE459647T1 (de) 2010-03-15

Family

ID=33300018

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04759472T ATE459647T1 (de) 2003-04-15 2004-04-13 Humane il-18 substitutionsmutanten und deren konjugate

Country Status (9)

Country Link
US (2) US7311902B2 (de)
EP (2) EP2261244A3 (de)
JP (2) JP4753867B2 (de)
AR (1) AR044024A1 (de)
AT (1) ATE459647T1 (de)
DE (1) DE602004025799D1 (de)
ES (1) ES2340494T3 (de)
TW (1) TW200510454A (de)
WO (1) WO2004091517A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026265A2 (en) 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
US20100061958A1 (en) * 2006-09-14 2010-03-11 The Trustees Of The University Of Pennsylvania Modulation of Regulatory T Cells by Human IL-18
CA2663300C (en) * 2006-09-15 2014-10-07 Creabilis Therapeutics S.P.A. Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
WO2008054585A2 (en) 2006-09-28 2008-05-08 Schering Corporation Use of pegylated il-10 to treat cancer
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
EP2185188B1 (de) 2007-08-22 2014-08-06 Medarex, L.L.C. Ortsspezifische bindung von wirkstoffen oder anderen mitteln an gentechnisch hergestellte antikörper mit c-terminalen erweiterungen
US8168165B2 (en) * 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
ME02842B (de) 2009-03-05 2018-01-20 Squibb & Sons Llc Cadm1-spezifische vollständig humane antikörper
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
CN102507824B (zh) * 2011-11-01 2013-10-09 北京三元基因工程有限公司 聚乙二醇修饰蛋白质的修饰位点分析方法
SG11201404667XA (en) 2012-02-13 2014-09-26 Bristol Myers Squibb Co Enediyne compounds, conjugates thereof, and uses and methods therefor
SI2956173T1 (sl) 2013-02-14 2017-06-30 Bristol-Myers Squibb Company Spojine tubulizina, postopki pridobivanja in uporaba
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
ES2941234T3 (es) 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
ES2747386T3 (es) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
ES2902179T3 (es) 2016-08-19 2022-03-25 Bristol Myers Squibb Co Compuestos de seco-ciclopropapirroloindol, conjugados de anticuerpo-fármaco de los mismos y métodos de elaboración y uso
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
SG11202001384TA (en) * 2017-09-06 2020-03-30 Univ Yale Interleukin-18 variants and methods of use
KR102771546B1 (ko) 2017-11-08 2025-02-21 야페이 상하이 바이오로지 메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드 생체분자의 컨쥬게이트 및 이의 용도
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
CN111378026A (zh) * 2018-12-27 2020-07-07 天津键凯科技有限公司 一种制备结合位点可控的peg化生物分子的方法
KR20210126037A (ko) 2019-02-08 2021-10-19 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 피부, 모발, 손톱 및/또는 점막의 처치 및/또는 관리에 유용한 화합물
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
WO2021141986A1 (en) * 2020-01-07 2021-07-15 St. Jude Children's Research Hospital, Inc. Chimeric gmcsf-il18 receptor
US20220056091A1 (en) * 2020-08-19 2022-02-24 Bright Peak Therapeutics Ag Modified il-18 polypeptides and uses thereof
CA3197145A1 (en) * 2020-11-02 2022-05-05 Aaron RING Interleukin-18 variants and methods of use
EP4293039A4 (de) * 2021-02-10 2025-07-16 Univ Nagasaki Neue humane interleukin-18 variante und deren verwendung
JP2023024168A (ja) 2021-08-06 2023-02-16 国立大学法人 長崎大学 がんの治療剤
WO2023118497A1 (en) * 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
EP4482531A1 (de) 2022-02-23 2025-01-01 Bright Peak Therapeutics AG Immunantigenspezifische il-18-immunzytokine und verwendungen davon
WO2023161853A1 (en) * 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
US20240132563A1 (en) 2022-02-23 2024-04-25 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
AU2023224445A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Modified il-18 polypeptides
WO2024051728A1 (en) * 2022-09-06 2024-03-14 I-Mab Biopharma Co., Ltd. Il-18 variant polypeptides
WO2024102587A2 (en) * 2022-11-11 2024-05-16 Mural Oncology, Inc. Interleukin 18 variants
CN116083572A (zh) * 2022-11-25 2023-05-09 广州希灵生物科技有限公司 一种检测il18基因启动子甲基化生物标志物的引物的应用
WO2025041095A2 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Il-18 polypeptides modified with polymers
WO2025041102A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
US20250197467A1 (en) 2023-08-23 2025-06-19 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025188694A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Tricyclic tlr7 agonists and uses thereof
US20250282776A1 (en) 2024-03-05 2025-09-11 Bristol-Myers Squibb Company Bicyclic TLR7 Agonists and Uses Thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US604630A (en) 1898-05-24 Avilliam
CS173849B1 (de) 1974-04-25 1977-03-31
US4436543A (en) 1982-06-03 1984-03-13 Kasten Harold B Neck ring mold apparatus for glass bottle manufacture
US4487325A (en) 1982-07-06 1984-12-11 Owens-Illinois, Inc. Crown closures and containers
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JPH06506217A (ja) 1991-03-18 1994-07-14 エンゾン,インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US6274552B1 (en) * 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5747446A (en) 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6060283A (en) 1996-06-27 2000-05-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding human interleukin-18 (IL-18, interferon-γ inducing factor)
JPH1080270A (ja) 1996-07-19 1998-03-31 Hayashibara Biochem Lab Inc ポリペプチドをプロセッシングする酵素
TW515843B (en) 1996-07-25 2003-01-01 Hayashibara Biochem Lab Process for producing an active polypeptide inducing interferon-γ production
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US5851798A (en) 1997-01-27 1998-12-22 Smithkline Beecham Corporation Nucleic acid encoding human GPR14 receptor
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6955811B2 (en) * 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
ATE279430T1 (de) 1998-03-05 2004-10-15 Chiron Corp Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
ATE526401T1 (de) 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
AU782496B2 (en) 1999-07-13 2005-08-04 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
CN1318443C (zh) 2000-05-16 2007-05-30 博尔德生物技术公司 含游离半胱氨酸残基的蛋白重折叠的方法
CZ20024085A3 (cs) 2000-06-15 2003-05-14 Smithkline Beecham Corporation Způsob přípravy fyziologicky aktivního IL-18 polypeptidu
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US7253260B2 (en) 2002-04-17 2007-08-07 Smithkline Beecham Corporation Human IL-18 crystal structure
US20040136992A1 (en) * 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
GB0323968D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions

Also Published As

Publication number Publication date
JP2007526207A (ja) 2007-09-13
WO2004091517A2 (en) 2004-10-28
DE602004025799D1 (de) 2010-04-15
EP2261244A3 (de) 2011-02-23
US7736639B2 (en) 2010-06-15
JP2011105737A (ja) 2011-06-02
TW200510454A (en) 2005-03-16
EP2261244A2 (de) 2010-12-15
US7311902B2 (en) 2007-12-25
WO2004091517A3 (en) 2006-07-27
EP1613274A2 (de) 2006-01-11
EP1613274B1 (de) 2010-03-03
US20050008615A1 (en) 2005-01-13
EP1613274A4 (de) 2008-04-16
JP4753867B2 (ja) 2011-08-24
ES2340494T3 (es) 2010-06-04
AR044024A1 (es) 2005-08-24
US20080206189A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
ATE459647T1 (de) Humane il-18 substitutionsmutanten und deren konjugate
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
IS7948A (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
DE60316737D1 (de) Parallelstangenmechanismus und damit versehenes künstliches Gelenk
DE602004020474D1 (de) Vegf-traps und deren therapeutische anwendungen
MA29079B1 (fr) Fusions et conjugues medicamenteux
DE60331861D1 (de) Ultraschallverfahren und ultraschallgerät
NO20052524D0 (no) Aminerte isofiavonoidderivater og anvendelse derav
FR2864080B1 (fr) Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
IS8074A (is) Setin 1,4- Díazepín og notkun theirra
DE502004004173D1 (de) Silber-legierung und deren Verwendung
FR2854633B1 (fr) Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
FR2882054B1 (fr) Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
NO20161485A1 (no) Kationiske bakterieklorofyllderivater og anvendelser derav
DK1513835T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
EP1646388A4 (de) Zytotoxische indeno- und isoindoloisochinolone
DE602004008668D1 (de) Benzoxazinderivate und deren verwendungen
IL185586A0 (en) 1,2,4-triazine derivatives, preparation and use thereof in human therapy
DE10338270B4 (de) Variator und Variatoranordnung
DE602004002571D1 (de) Spektrophotometer und dessen baugruppen
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
DE602004022169D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
FR2891825B1 (fr) Derives de la 1-amino-isoquinoline, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties